7:41 PM
 | 
Dec 03, 2012
 |  BC Extra  |  Clinical News

Bristol-Myers discontinues Alzheimer's compound avagacestat

Bristol-Myers Squibb Co. (NYSE:BMY) discontinued development of avagacestat ( BMS-708163) after data from Phase II trials evaluating the product for mild to moderate Alzheimer's disease...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >